Impact of ranolazine on ventricular arrhythmias – a systematic review

George Bazoukis; Gary Tse; Konstantinos P. Letsas; Costas Thomopoulos; Katerina K. Naka; Panagiotis Korantzopoulos; Xenophon Bazoukis; Paschalia Michelongona; Stamatis S. Papadatos; Konstantinos Vlachos; Tong Liu; Michael Efremidis; Adrian Baranchuk; Stavros Stavrakis; Costas Tsioufis

doi:10.1002/joa3.12031

Impact of ranolazine on ventricular arrhythmias – a systematic review

George Bazoukis, Gary Tse, Konstantinos P. Letsas, Costas Thomopoulos, Katerina K. Naka, Panagiotis Korantzopoulos, Xenophon Bazoukis, Paschalia Michelongona, Stamatis S. Papadatos, Konstantinos Vlachos, Tong Liu, Michael Efremidis, Adrian Baranchuk, Stavros Stavrakis, Costas Tsioufis

Research output: Contribution to journal › Review article › peer-review

9 Citations (Scopus)

Abstract

Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.

Original language	English
Pages (from-to)	124-128
Number of pages	5
Journal	Journal of Arrhythmia
Volume	34
Issue number	2
DOIs	https://doi.org/10.1002/joa3.12031
Publication status	Published - 1 Apr 2018
Externally published	Yes

Keywords

Anti-arrhythmic drugs
Ranolazine
Ventricular arrhythmias
Ventricular fibrillation
Ventricular tachycardia

Access to Document

10.1002/joa3.12031

Cite this

Bazoukis, G., Tse, G., Letsas, K. P., Thomopoulos, C., Naka, K. K., Korantzopoulos, P., Bazoukis, X., Michelongona, P., Papadatos, S. S., Vlachos, K., Liu, T., Efremidis, M., Baranchuk, A., Stavrakis, S., & Tsioufis, C. (2018). Impact of ranolazine on ventricular arrhythmias – a systematic review. Journal of Arrhythmia, 34(2), 124-128. https://doi.org/10.1002/joa3.12031

@article{e8275aef3f34446ba986ad57a984e469,

title = "Impact of ranolazine on ventricular arrhythmias – a systematic review",

abstract = "Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.",

keywords = "Anti-arrhythmic drugs, Ranolazine, Ventricular arrhythmias, Ventricular fibrillation, Ventricular tachycardia",

author = "George Bazoukis and Gary Tse and Letsas, {Konstantinos P.} and Costas Thomopoulos and Naka, {Katerina K.} and Panagiotis Korantzopoulos and Xenophon Bazoukis and Paschalia Michelongona and Papadatos, {Stamatis S.} and Konstantinos Vlachos and Tong Liu and Michael Efremidis and Adrian Baranchuk and Stavros Stavrakis and Costas Tsioufis",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors.",

year = "2018",

month = apr,

day = "1",

doi = "10.1002/joa3.12031",

language = "English",

volume = "34",

pages = "124--128",

number = "2",

}

TY - JOUR

T1 - Impact of ranolazine on ventricular arrhythmias – a systematic review

AU - Bazoukis, George

AU - Tse, Gary

AU - Letsas, Konstantinos P.

AU - Thomopoulos, Costas

AU - Naka, Katerina K.

AU - Korantzopoulos, Panagiotis

AU - Bazoukis, Xenophon

AU - Michelongona, Paschalia

AU - Papadatos, Stamatis S.

AU - Vlachos, Konstantinos

AU - Liu, Tong

AU - Efremidis, Michael

AU - Baranchuk, Adrian

AU - Stavrakis, Stavros

AU - Tsioufis, Costas

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.

AB - Ranolazine is a new medication for the treatment of refractory angina. However, except its anti-anginal properties, it has been found to act as an anti-arrhythmic. The aim of our systematic review is to present the existing data about the impact of ranolazine in ventricular arrhythmias. We searched MEDLINE and Cochrane databases as well clinicaltrials.gov until September 1, 2017 to find all studies (clinical trials, observational studies, case reports/series) reported data about the impact of ranolazine in ventricular arrhythmias. Our search revealed 14 studies (3 clinical trials, 2 observational studies, 8 case reports, 1 case series). These data reported a beneficial impact of ranolazine in ventricular tachycardia/fibrillation, premature ventricular beats, and ICD interventions in different clinical settings. The existing data highlight the anti-arrhythmic properties of ranolazine in ventricular arrhythmias.

KW - Anti-arrhythmic drugs

KW - Ranolazine

KW - Ventricular arrhythmias

KW - Ventricular fibrillation

KW - Ventricular tachycardia

UR - http://www.scopus.com/inward/record.url?scp=85051174046&partnerID=8YFLogxK

U2 - 10.1002/joa3.12031

DO - 10.1002/joa3.12031

M3 - Review article

AN - SCOPUS:85051174046

SN - 1880-4276

VL - 34

SP - 124

EP - 128

JO - Journal of Arrhythmia

JF - Journal of Arrhythmia

IS - 2

ER -

Impact of ranolazine on ventricular arrhythmias – a systematic review

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this